Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Post by grover11on Aug 06, 2014 8:13am

272 Views

Post# 22812626

TKMR pre market

Pre-Market Time (ET)	Pre-Market Price	Pre-Market Share Volume
08:05	$ 14.30	100
08:00	$ 14.30	76
08:00	$ 14.40	350
08:00	$ 14.50 High	500
08:00	$ 14.30	100
08:00	$ 14.29	100
08:00	$ 14.20	474
08:00	$ 14.18	150
08:00	$ 14.17	100
07:34	$ 13.82 Low	500
07:28	$ 14.39	100
06:42	$ 14.50	85
06:38	$ 14.50	315
06:22	$ 14.49	100